● Live Wisconsin AG suit vs Kalshi & Polymarket pending · NY/IL insider-trading orders in effect · Updated May 2026
← News & Updates
Regulation

Kalshi and Polymarket Expand Into Health Contracts — Measles, Drug Trials, FDA Approvals Draw Scrutiny

Kalshi and Polymarket have added event contracts tied to US public health outcomes, including measles case-count thresholds settled using CDC data, clinical drug-trial results, and FDA regulatory approvals. Two Democratic senators wrote to the Department of Health and Human Services on November 11 raising concerns about the drug-trial and FDA markets, particularly the risk that people with confidential access to trial data or agency decisions could profit from disclosing it. Kalshi says it has implemented guardrails, such as limiting markets to late-stage trials. The expansion extends the debate over whether some prediction market categories commodify sensitive public outcomes in harmful ways.

Kalshi and Polymarket have expanded into US public health outcomes. Polymarket's international platform, which operates separately from its US entity, lists a 2026 measles market settled using Centers for Disease Control and Prevention case counts, and Kalshi lists contracts with thresholds for the 2026 US measles total. Both have also added contracts tied to clinical drug-trial results and Food and Drug Administration approvals. The expansion follows the platforms' pattern of extending into every category of measurable future outcome, but health contracts raise distinct concerns because they touch matters — disease outbreaks, drug approvals, agency decisions — where the information environment is tightly controlled and the real-world stakes extend well beyond the traders.

For UK readers, the clinical-trial and FDA-approval contracts are the sharpest concern, and they have a clear UK analogue in the insider-dealing rules around pharmaceutical announcements. Two Democratic senators wrote to the Department of Health and Human Services on November 11 asking what measures it has taken to mitigate risks from prediction markets on drug trials and approvals. The core issue is insider information: trials and regulatory decisions involve a defined set of people — investigators, pharmaceutical employees, agency reviewers — who hold material non-public information that moves the contracts. A contract on whether a trial will succeed, or whether the FDA will approve a product, creates a direct incentive for insiders to trade on or leak confidential information. Researchers warn such contracts could reward those with confidential access for disclosing it, undermining both market integrity and the confidentiality that clinical research and regulatory review depend on.

Kalshi has defended the contracts with guardrails and an informational-access argument. It says it limits drug-trial markets to late-stage trials, where more information is already public and the universe of material non-public information is narrower, and a spokesperson framed the pilot as broadening access to drug-development information — the same forecasting-value argument the platforms make across all categories. The claim is that aggregating dispersed expectations about a drug's prospects produces a useful public signal, as prediction markets on economic data or elections do. The counterargument is that drug development and public health are domains where the harm from insider trading and information leakage is more concrete than in politics or sport: a leaked trial result can move a pharmaceutical company's share price, affect patients' treatment decisions, and compromise the controlled-disclosure process regulators rely on, in ways a leaked election forecast does not.

The measles contracts raise a different and more uncomfortable concern. Betting on the number of measles cases attaches a financial position to the course of a disease outbreak, which critics argue is corrosive regardless of direction — a position that profits from more cases is ghoulish, and one that profits from fewer cases could in principle create perverse incentives around the public-health interventions that reduce case counts. One commentary noted that an outbreak resolved by public-health intervention could look like market manipulation to critics, illustrating how poorly the manipulation framework designed for financial contracts maps onto public-health outcomes. The health-contract expansion is the clearest recent example of the broader critique that prediction markets are extending into domains of public life where commodifying outcomes is ethically fraught, and where the platforms' standard defences — forecasting value, insider-trading guardrails, voluntary participation — fit awkwardly. As the platforms keep broadening their range in search of volume, the health contracts will sharpen the question of whether some categories of outcome should be off-limits to a prediction market, even one otherwise legally permitted to operate.

Recent updates


CFTC Orders Kalshi to Halt 'Trump Mention' Markets — the Agency Restrains Its Own Protégé

The CFTC notified Kalshi that its 'mention' markets — contracts on what President Trump will say — are under a formal stay, forcing an indefinite pause pending a review of whether the contracts are 'readily susceptible to manipulation.' Kalshi has until December 11 to defend the products, and its CEO reportedly disagrees with the suspension. The action is notable because the CFTC has spent 2026 defending Kalshi against state enforcement; here the same agency is restricting one of Kalshi's own product lines.

Fourth Circuit Rules Against Kalshi in Maryland — Circuit Split Widens to 3-1 With a Notable Dissent

A divided Fourth Circuit panel ruled 2-1 on November 17 that Maryland gaming regulators can pursue enforcement against Kalshi over unlicensed sports betting, rejecting the platform's CFTC-preemption argument. Judge DeAndrea Benjamin dissented, arguing that Kalshi's sports event contracts are 'swaps' under exclusive CFTC oversight — the first appellate dissent on the pro-Kalshi side. The ruling makes the Fourth Circuit the third appeals court to rule against Kalshi, deepening the split to three circuits against (Fourth, Sixth, Ninth) and one for (Third), with the Supreme Court cert petition pending.

CFTC and DOJ Sue Louisiana and Arkansas as Federal-State Fight Turns Openly Hostile

Louisiana Attorney General Liz Murrill won a temporary restraining order on November 12 against 31 prediction market entities, including Kalshi, Polymarket, Robinhood, and Coinbase, with a preliminary injunction hearing set for November 30. The CFTC — now joined by the Department of Justice — sued both Louisiana and Arkansas to block the state enforcement, marking Louisiana as the twelfth state the agency has taken to court. The dispute has turned personal: Murrill called CFTC Chairman Michael Selig an 'obsequious standard bearer' for the platforms, while Selig characterised her lawsuit as 'naked lawfare.' The DOJ's involvement escalates the federal response beyond the CFTC acting alone.